Physicians disagree with acetaminophen restrictions
This article was originally published in The Tan Sheet
Executive Summary
A large majority -- 82 percent -- of recently surveyed physicians does not agree that FDA should pull acetaminophen products off the market. HCD Research surveyed 589 physicians July 17-19 after a joint advisory panel recommended FDA remove prescription acetaminophen products from the market, but said OTC combo products could stay. It also advised the agency restrict the amount of acetaminophen in OTC tablets and lower the dose (1"Health News Daily" July 1, 2009). While 86 percent of the physicians said the panel's recommendation will not change whether they will continue prescribing acetaminophen Rx drugs or recommending OTC drugs for their patients, nearly a third -- 29 percent -- said they are more likely to discuss warnings and dosage instructions with patients who use acetaminophen products, Flemington, N.J.-based HCD said July 20
You may also be interested in...
UNPA On Team Awarded $300,000 US Grant For Project To Improve Natural Health Trade With China
Grant from Department of Commerce Market Development Cooperator Program funds project for four years. In addition to grant, the project partners – UNPA, National Animal Supplement Council, Eurofins Scientific testing company and China Inspections and Testing Society – get DoC assistance.
Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
Novartis Takes Huntington's Path With SMA Therapy Branaplam
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: